WeChat Mini Program
Old Version Features

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard '7+3' Induction Therapy in Newly Diagnosed AML: Results from the SAL-MODULE Phase I Study

Christoph Roellig,Christoph Schliemann,Leo Ruhnke,Lars Fransecky, Bjorn-Niklas Heydrich,Maher Hanoun,Richard Noppeney,Kerstin Schaefer-Eckart,Knut Wendelin,Jan-Henrik Mikesch,Jan Moritz Middeke,Manja Reimann,Frank Fiebig,Sven Zukunft,Martin Wermke,Hubert Serve,Uwe Platzbecker,Carsten Mueller-Tidow,Claudia D. Baldus,Martin Bornhaeuser

British Journal of Haematology（2024）

Cited 0|Views43
Key words
AML,gemtuzumab ozogamicin,induction therapy,intensive therapy,midostaurin
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined